Souhaitez-vous accéder aux communiqués récents ?

Investors who lost money in IBRX after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.

• Plan to resume enrollment in clinical study of lorigerlimab in gynecologic cancers   • On track to provide mid-2026 program update  ROCKVILLE, MD, April 08, 2026 (GLOBE NEWSWIRE) -- MacroGenics,...

RAANANA, ISRAEL, April 08, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today...

Austin, United States, April 08, 2026 (GLOBE NEWSWIRE) -- SNS Insider reported that global Flow Cytometry Market was valued at USD 5.75 billion in 2025 and is expected to reach USD 12.19 billion by...

A single-dose of Trogenix’s proprietary Synthetic Super-Enhancers achieved complete tumour elimination in 83% of treated cases with no toxicity over 11 months and no tumour recurrence in a brain...

Spider silk’s extraordinary combination of strength, elasticity, toughness, biocompatible, biodegradable, and low weight, properties that outperform Kevlar

China National Intellectual Property Administration has granted a patent covering potency assay methods for assessing human mesenchymal stem cells (MSCs).

VANCOUVER, British Columbia, April 08, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary — Biotechs that went public in Q1 2026 raised a median of $287.5 million each; and nearly every one...

Strong participation in recent $33 million common stock offering highlights investor confidence in late-stage clinical momentum and commercial potential Statistical assessments point to high...

NEW YORK, USA, April 08, 2026 (GLOBE NEWSWIRE) -- Zion Market Research has published a new research report titled “Functional Service Providers Market By Type (Clinical Monitoring, Medical Writing,...